Labcorp® Plasma Detect™ now available for clinical use to assess risk of recurrence in stage III colon cancer patients
FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx now available to support treatment selection
BURLINGTON, N.C., April 23, 2025 -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio with two solutions: Labcorp Plasma Detect for clinical use to help assess the risk of disease recurrence in stage III colon cancer patients, and the availability of PGDx elio plasma focus Dx, the first and only kitted, pan-solid tumor liquid biopsy test authorized by the U.S. Food and Drug Administration (FDA) to identify patients who may benefit from targeted treatments.
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
